EXEL News and Press, Exelixis Inc. From 03/03/22

The United States economy is growing strongly, outperforming other developed economies. Furthermore, analysts believe the country is well-positioned to weather economic challenges created by the Russia-Ukraine war. So, we think that growth stocks Vertex Pharmaceuticals (VRTX), Fair Isaac (FIC...

- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March: Cowen 42 nd Annual Healthca...

The outlook for the pharmaceutical and biotech industry is good thanks to resilience versus crises and large macro tailwinds. XBI and many biotech names have sold off a lot over the last year. The ETF is now trading lower than before the pandemic. XBI's approach is different from ...

100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...

A federal court judge in Delaware has denied a motion from MSN Labs to add three additional patents to an existing case against Exelixis (EXEL -0.4%) regarding Cabometyx (cabozantinib). The existing case involves the '776 patent, which covers the active ingredient in Cabometyx. That trial is ...

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...

Biopharma stocks have been trading at lower valuations because of uncertainties surrounding drug-pricing reform, regulatory surprises, and COVID-19. However, the biopharma industry is expected to grow in the coming years. Given the bullish analysts’ sentiment around the sector, biophar...

Today, we revisit the mid-cap oncology name Exelixis after the company just posted better than expected quarterly results. The company continues to grow its blockbuster franchise CABOMETYX and has a huge cash hoard, yet the stock has been stuck in a long-term trading range. We upd...

Exelixis (EXEL +8.1%) Q4 2021 results beat on the top and bottom lines after the closing bell Thursday, and Street firms are responding positively. While maintaining its buy rating, H.C. Wainwright reduced its target to $42 from $52 (~129% upside based on Friday's close). RBC Capital Mar...

Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q4 2021 Earnings Call Feb 17, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q4 2021 Earnings Call Transcript